US House reform bill requires government negotiation of Part D drug prices
This article was originally published in Scrip
Executive Summary
The US House's $894 billion, consolidated healthcare reform measure would require the US government to negotiate Medicare Part D drug prices and pharmaceutical companies to provide drug rebates for individuals dually eligible for both Medicare and Medicaid.